Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/209285
Title: | TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism |
Author: | Canyelles, Marina Plaza, Melania Rotllan, Noemi Llobet i Lorente, Ma. Dolors Julve, Josep Mojal, Sergi Díaz Ricart, Maribel Soria, José Manuel Escolà Gil, Joan Carles Tondo i Colomer, Mireia Blanco Vaca, Francisco Souto Andrés, Juan Carlos |
Keywords: | Tromboembolisme Espectroscòpia Thromboembolism Spectrum analysis |
Issue Date: | 10-Jul-2023 10-Jul-2023 |
Publisher: | MDPI |
Abstract: | Background: The present work evaluates the association between circulating concentrations of Trimethylamine-N-oxide (TMAO), gamma butyrobetaine (gamma BB), and trimetyllisine (TML) in controls and patients with venous thromboembolism (VTE) with coagulation parameters. Methods: The study involved 54 VTE patients and 57 controls. Platelet function, platelet hyperreactivity, platelet adhesiveness, thrombosis-associated parameters, and thrombin generation parameters were studied. Plasma TMAO, gamma BB, and TML determination was performed using an ultra-high-performance liquid chromatography system coupled with mass spectrometry. Results: No differences were found for TMAO, gamma BB, or TML concentrations between controls and VTE patients. In thrombin generation tests, TMAO, gamma BB, and TML showed a positive correlation with lag time and time to peak. TMAO, gamma BB, and TML negatively correlated with peak height. No significant differences were observed regarding TMAO, gamma BB, and TML concentrations between the two blood withdrawals, nor when the control and VTE patients were analyzed separately. No correlation was observed between these gut metabolites and platelet function parameters. Conclusions: No differences were found regarding TMAO, gamma BB, and TML concentrations between the control and VTE groups. Some correlations were found; however, they were mild or went in the opposite direction of what would be expected if TMAO and its derivatives were related to VTE risk. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/jcm11051425 |
It is part of: | Journal Of Clinical Medicine, 2022, vol. 11, num. 5, |
URI: | http://hdl.handle.net/2445/209285 |
Related resource: | https://doi.org/10.3390/jcm11051425 |
ISSN: | 2077-0383 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk_ClinicalMedicine.pdf | 1.16 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License